Author | Study description | Treatment | Patient population | % 1L | % 2L | % 3L+ | N | ORR % | PFS months | OS months | % TNBC patients |
---|
Tutt et al. [19] | Phase III TNT | Car | 2L+ mTNBC | | 100 | 59 | 31.4 | 3.1 | 12.4 | 100 |
Doc | | | | 64 | 34.0 | 4.5 | 12.3 | 100 |
Kim et al. [15] and Dent et al. [14] | Phase II LOTUS | Pac+Ipatasertib | 1L mTNBC | 100 | | | 62 | NR | 6.2 | NR | 100 |
Pac | 1L mTNBC | 100 | | | 62 | NR | 4.9 | NR | 100 |
Schmid et al. [10] | Phase III IMpassion130 | Atezolizumab plus nab-paclitaxel | 1L mTNBC | 100 | | | 451 | NR | 7.2 | 21.3 | 100 |
nab-paclitaxel | 1L mTNBC | 100 | | | 451 | NR | 5.5 | 17.6 | 100 |
Robson et al. [17, 18] | Phase III OLYMPIAD | Olaparib | 1L–2L mBC | | 100 | 205 | NR | 7.0 | 19.3 | 49.8 |
Physician’s-Choice | 1L–2L mBC | | | | 97 | NR | 4.2 | 17.1 | 49.5 |
Litton et al. [16] | Phase III EMBRACA | Talazoparib | 2L+ locally advanced BC | | 100 | 287 | 62.6 | 8.6 | NR | 45.3 |
Physician’s-Choice | 2L+ locally advanced BC | | | | 144 | 27.2 | 5.6 | NR | 41.7 |
- 1L first-line, 2L second-line, BC breast cancer, Car carboplatin, Doc docetaxel, mTNBC metastatic triple-negative breast cancer, N/R not reported, ORR objective response rate, OS overall survival, Pac paclitaxel, PFS progression-free survival, TNBC triple-negative breast cancer